Vir Biotechnology, Inc.
VIR · Nasdaq · USD · Market cap $1.7B · 367 employees
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price8.39 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.51x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.29)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.29, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Vir Biotechnology, Inc. holds its Markup at $8.39. Elevated stress, defensive posture warranted, held for 3 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 3 days |
| Price at the screen | $8.39 |
| Valuation | N/A trailing · -3.87 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.74 |
Five Screens: VIR's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 9.76% | Below 33% | Pass |
| Interest-bearing cash | 31.37% | Below 33% | Pass |
| Receivables | 23.15% | Below 49% | Pass |
| Revenue purity | 60.49% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Vir Biotechnology, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 60% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when VIR's ethical verdict changes
Today VIR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.51x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 8 covering, consensus Strong Buy. Average target +174%.
Clinical stage bets rarely deliver on paper promise
A company whose entire value sits in unproven drugs for infectious diseases is like funding a race car that has never left the workshop. Vir Biotechnology trades at half our calculated fair value with a forward multiple that reflects deep losses, yet the opportunity rating stays at none because clinical pipelines this early carry failure rates that wipe out capital fast.
The business shows zero profit margins and a negative return on equity of 48 percent, which is normal for a firm still burning cash on trials. Even with an ethical screen that passes cleanly and analyst targets clustered around 21 dollars, the absence of any moat or commercial product leaves the upside looking more like a lottery ticket than a repeatable business.
Risk sits in the binary outcomes of late stage data and dilution that often follows missed milestones. Currency or market swings matter less here than the simple fact that most such pipelines never reach paying customers. Analysis, not advice.
| Forward P/E | -3.9x |
| EPS, trailing | -1.18 |
| EPS, forward | -2.39 |
| Profit margin | -61.0%currently unprofitable |
| Return on equity | -21.8%not currently earning a positive return on equity |
| FCF yield | -4.75% |
| Debt to equity | 0.10minimal debt: a conservative balance sheet |
| Current ratio | 6.30comfortably covers its short-term bills |
| Beta | 1.74much more volatile than the market |
| Short interest, float | 0.10% |
| 52-week range | 5.32 - 14.38 |
| Market cap | $1.7B |
| Employees | 367 |
VIR-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from markdown to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale Yahoo Finance · 8d ago
- Vir Biotechnology stock tumbles on $150M share offering Yahoo Finance · 8d ago
- Vir Biotechnology Announces Pricing of Public Offering of Common Stock Yahoo Finance · 9d ago
- Vir Biotechnology Announces Proposed Public Offering Yahoo Finance · 9d ago
- Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-15 | Mike Kelly | Republican | sell | 50K–100K |
| 2026-10-15 | Ro Khanna | Democrat | buy | 50K–100K |
| 2026-10-15 | Mike Kelly | Republican | sell | 50K–100K |
| 2026-10-13 | Ro Khanna | Democrat | buy | 50K–100K |
| 2026-09-23 | Kevin Hern | Republican | sell | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.29 | -11.2% | · | $888 | -11.2% |
| 2 months | $9.50 | -13.2% | · | $868 | -13.2% |
| 3 months | $9.48 | -13.0% | · | $870 | -13.0% |
| 6 months | $6.63 | +24.4% | · | $1,244 | +24.4% |
| 1 year | $5.42 | +52.2% | · | $1,522 | +52.2% |
| 2 years | $11.21 | -26.4% | · | $736 | -26.4% |
| 3 years | $25.43 | -67.6% | · | $324 | -67.6% |
| 5 years | $45.53 | -81.9% | · | $181 | -81.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever VIR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.